Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.46M | 6.63M | 6.18M | 6.12M | 6.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.98M | 19.67M | 20.50M | 21.26M | 22.22M |
| Operating Income | -17.98M | -19.67M | -20.50M | -21.26M | -22.22M |
| Income Before Tax | -17.12M | -18.92M | -19.25M | -19.88M | -20.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.12 | -18.92 | -19.25 | -19.88 | -20.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.12M | -18.92M | -19.25M | -19.88M | -20.78M |
| EBIT | -17.98M | -19.67M | -20.50M | -21.26M | -22.22M |
| EBITDA | -17.96M | -19.65M | -20.48M | -21.24M | -22.20M |
| EPS Basic | -1.57 | -1.75 | -1.78 | -1.84 | -1.93 |
| Normalized Basic EPS | -0.99 | -1.10 | -1.12 | -1.16 | -1.20 |
| EPS Diluted | -1.57 | -1.75 | -1.78 | -1.84 | -1.93 |
| Normalized Diluted EPS | -0.99 | -1.10 | -1.12 | -1.16 | -1.20 |
| Average Basic Shares Outstanding | 32.40M | 43.28M | 43.21M | 43.19M | 43.15M |
| Average Diluted Shares Outstanding | 43.24M | 43.28M | 43.21M | 43.19M | 43.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |